Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
These Stocks Are Moving the Most Today: Roivant Sciences, Textainer, Okta, Microsoft, Alphabet
2023-10-23 16:50
Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
You Might Like...
The 5 best dating sites for seniors: Find love in your golden years
NBA 2K24 Best Controller Settings: Current and Next Gen
Valorant Deadlock Recruitment Event End Date
Tech Earnings Kick Off This Week With Netflix. AI Is Now a Risk.
Somalia TikTok: Government's planned ban leaves creators anxious
Hustlers University: Exploring controversial internet personality Andrew Tate's brainchild
GoDaddy Web Hosting Review
Robotaxis can now trundle the streets of San Francisco 24/7